University of Ulsan College of Medicine Reports Findings in Cell Transplants (Ten-Year Trends of Hematopoietic Stem Cell Transplantation in Korean Pediatric Cancer from the National Health Insurance Claims Data): Transplant Medicine – Cell Transplants

2023 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Transplant Medicine - Cell Transplants is the subject of a report. According to news originating from Seoul, South Korea, by NewsRx correspondents, research stated, “We aimed to determine the current application and survival trends of hematopoietic stem cell transplantation (HSCT) among Korean children and adolescents with cancer. Data of patients aged <20 years with KCD-10 C-codes and specific designation codes were collected from the National Health Insurance Service database.”

Our news journalists obtained a quote from the research from the University of Ulsan College of Medicine, “Thirty claim codes for HSCT were included, and data from 2009 to 2019 were analyzed. The operational definition of pediatric cancer yielded an annual average of 2,000, with annual cases decreasing. In 2019, 221 HSCTs were performed, a decrease from the ten-year average of 276. Allografts outnumbered autografts with a ratio of 1.5:1. The source of allograft was bone marrow in 15% of patients in 2009; however, it substantially decreased to 3.3% in 2019. Furthermore, 70.5% of allogeneic HSCT used peripheral blood stem cell (PBSC) grafts, which increased to 89.3% by 2015. Cord blood utilization markedly decreased to 2.7% in 2018. The 5-year overall survival (OS) rate of all patients was 85.1%. Overall mortality decreased among patients who underwent recent HSCT, and they exhibited a higher 5-year OS rate. In Korea, the number of pediatric patients with cancer is declining; however, the ratio of transplants to all patients remains constant. Patients who recently underwent transplantation showed better survival rates, possibly due to HSCT optimization. Korea showed a substantially greater PBSC utilization in pediatric HSCT.”

According to the news editors, the research concluded: “An in-depth examination encompassing donor relations and cause of death with a prospective registry is required in future studies.”

This research has been peer-reviewed.

For more information on this research see: Ten-Year Trends of Hematopoietic Stem Cell Transplantation in Korean Pediatric Cancer from the National Health Insurance Claims Data. Cancer Research and Treatment, 2023. Cancer Research and Treatment can be contacted at: Korean Cancer Association, Rm 1824, Gwanghwamun Officia, 92 Saemunan-Ro, Jongno-Gu, Seoul, 110-999, South Korea.

The news correspondents report that additional information may be obtained from Hwa Jung Kim, Dept. of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Additional authors for this research include Hyery Kim, Youngjun Jo, Su Hyun Yoon, Young Kwon Koh, Sunghan Kang, Kyung-Nam Koh and Ho Joon Im.

The publisher’s contact information for the journal Cancer Research and Treatment is: Korean Cancer Association, Rm 1824, Gwanghwamun Officia, 92 Saemunan-Ro, Jongno-Gu, Seoul, 110-999, South Korea.

(Our reports deliver fact-based news of research and discoveries from around the world.)